Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.

about

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.

Item

http://www.wikidata.org/entity/Q47548020

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical management and outcom ...... rying EGFR mutations in Spain.

@en

Clinical management and outcom ...... rying EGFR mutations in Spain.

@nl

type

Item

label

Clinical management and outcom ...... rying EGFR mutations in Spain.

@en

Clinical management and outcom ...... rying EGFR mutations in Spain.

@nl

prefLabel

Clinical management and outcom ...... rying EGFR mutations in Spain.

@en

Clinical management and outcom ...... rying EGFR mutations in Spain.

@nl

P1476

Clinical management and outcom ...... rying EGFR mutations in Spain.

@en

P2093

Alfredo Paredes

http://www.w3.org/2001/XMLSchema#string

Angel Artal

http://www.w3.org/2001/XMLSchema#string

David Vicente Baz

http://www.w3.org/2001/XMLSchema#string

Dolores Isla

http://www.w3.org/2001/XMLSchema#string

Francisco Aparisi

http://www.w3.org/2001/XMLSchema#string

Isidoro Barneto

http://www.w3.org/2001/XMLSchema#string

Javier Valdivia

http://www.w3.org/2001/XMLSchema#string

Jesús Manuel Andrade Santiago

http://www.w3.org/2001/XMLSchema#string

José Miguel Sánchez-Torres

http://www.w3.org/2001/XMLSchema#string

Maite Martínez Aguillo

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Benchmarking of mutation diagnostics in clinical lung cancer specimens

P2888

s12885-018-4004-7

P304

106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-018-4004-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mariano Provencio

Edurne Arriola

P577

2018-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100718347

http://www.w3.org/2001/XMLSchema#string

P698

29382302

http://www.w3.org/2001/XMLSchema#string

P932

5791371

http://www.w3.org/2001/XMLSchema#string